EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

Binod Dhakal iD, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence G Lum iD, Deborah D Glass, Jee Hyun Park, Michele Donato, David S Siegel, Tania C Felizardo, Daniel H Fowler

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2024-010649 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Binod Dhakal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, Milwaukee, Wisconsin, USA bdhakal@mcw.edu. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Multiple Myeloma, Sirolimus, Th1 Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (T CM ) whereas ex vivo IFN-α promotes type I cytokines, with each of these functions known to enhance the adoptive T cell therapy of cancer. Rapamycin-resistant T cells polarized for a type II cytokine phenotype were previously evaluated in the allogeneic transplantation context.

Methods

The clinical trial ( NCT04176380 ) evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma (RRMM).

Results

From December 2020 to December 2022, 14 patients with RRMM received a median of three RAPA-201 infusions (median dose, 80×10 6 cells). RAPA-201 drug products (DPs) were: polyclonal; enriched for T CM cells; reduced for immune checkpoint expression, including PD1, CD73, and LAIR1; and preferentially secreted Th1 cytokines. The median chemotherapy dose administered per cycle was 1,817 mg total for cyclophosphamide (range, 1,100–2,200) and 2.35 mg/M 2 for pentostatin (range, 0–16). Nine of 14 patients (64%) achieved disease remission, with eight partial responses and one stringent complete response. Median progression-free survival was 6.0 months (range, 2.1 to>16.8 months). There were no toxicities of any grade attributable to RAPA-201, including no cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome. Only 4 of 14 patients (29%) had a serious adverse event (≥ grade 3) of any attribution.

Conclusions

Consistent with our hypothesis, ex vivo manufacturing using mTOR inhibition and IFN-α polarization consistently yielded a novel RAPA-201 DP that possessed a desirable phenotype relative to cytokine phenotype, memory status, and checkpoint expression. RAPA-201 recipients had preservation of T cell counts and Th1 cytokine secretion yet had increased T cell receptor clonality that associates with antitumor responses in the setting of monoclonal antibody checkpoint therapy. RAPA-201 therapy overcomes previous barriers to effective autologous polyclonal T-cell therapy, as it is feasible to manufacture, exquisitely safe to administer, and mediates remission in patients with RRMM. Trial registration number ClinicalTrials.gov: NCT04176380 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveMultiple MyelomaSirolimusTh1 CellsAdultAgedFemaleHumansMaleMiddle AgedDrug Resistance, NeoplasmRemission Induction

Stichwörter der Autor:innen

ImmunotherapyMultiple Myeloma

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA bdhakal@mcw.edu.
  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Obsidian Therapeutics, Boston, Massachusetts, USA.
  • Mayo Clinic, Phoenix, Arizona, USA.
  • University of Virginia, Charlottesville, Virginia, USA.
  • Rapa Therapeutics, Rockville, Maryland, USA.

ORCID-Profile: Binod Dhakal, Lawrence G Lum

Zitieren

APA

Dhakal, B., Hari, P., Chhabra, S., Szabo, A., Lum, L. G., Glass, D. D., Park, J. H., Donato, M., Siegel, D. S., Felizardo, T. C., & Fowler, D. H. (2025). Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010649

Vancouver

Dhakal B, Hari P, Chhabra S, Szabo A, Lum LG, Glass DD, et al. Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010649

BibTeX
@article{Dhakal2025,
  author = {Dhakal, Binod and Hari, Parameswaran and Chhabra, Saurabh and Szabo, Aniko and Lum, Lawrence G and Glass, Deborah D and Park, Jee Hyun and Donato, Michele and Siegel, David S and Felizardo, Tania C and Fowler, Daniel H},
  title = {Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2024-010649}
}
Kostenlos starten →